Greg DiRusso, MD is the Medicine Team Lead for Hemophilia, leading the Global Medicine Teams for Pfizer hemophilia medicines: FIX gene therapy, FVIII gene therapy and anti-TFPI. Previously, he was the Global Clinical Lead for Eliquis, advancing programs in pediatric development, Eliquis in cardioversion for atrial fibrillation and factor Xa inhibitor reversal. Prior to joining Pfizer, Greg worked at Bristol-Myers Squibb, CSL Behring and Cytosorbents developing therapies in the areas of immunology, inflammation and cardiovascular disease. Before his industry career, Greg served on the surgical faculty at Primary Children’s Medical Center at the University of Utah and as Vice Chairman of Cardiovascular Surgery and Director of Cardiac Transplantation at Children’s National Medical Center.
3:30 PM - 4:25 PM (PDT)
Tuesday, June 9
The sharing of expertise and capabilities between internal R&D teams and external partners plays a…